A share price of Galectin Therapeutics Inc [GALT] is currently trading at $2.85, up 13.55%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GALT shares have gain 32.56% over the last week, with a monthly amount glided 115.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Buy rating on August 13, 2020, and elevated its price target to $12. On February 13, 2019, B. Riley FBR initiated with a Buy rating and assigned a price target of $11 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $10 on December 07, 2017. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $6 on November 28, 2017. In a note dated March 30, 2017, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $3.50.
Galectin Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.73 and $3.90. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $2.85 at the most recent close of the market.
Analyzing the GALT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -4.74, Equity is 0.46 and Total Capital is 0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.62 points at the first support level, and at 2.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.96, and for the 2nd resistance point, it is at 3.08.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Galectin Therapeutics Inc [NASDAQ:GALT] is 0.08. In addition, the Quick Ratio stands at 0.08 and the Cash Ratio stands at 0.07.
Transactions by insiders
Recent insider trading involved Shlevin Harold H., Director, that happened on Dec 30 ’24 when 6500.0 shares were purchased. Chief Medical Officer, Jamil Khurram completed a deal on Dec 23 ’24 to sell 13654.0 shares. Meanwhile, President and CEO LEWIS JOEL sold 56000.0 shares on Dec 23 ’24.
